The ongoing pandemic of the coronavirus disease 2019 (COVID-19) has claimed more than half-a-million lives and severely damaged the global economy. This severe acute respiratory syndrome (SARS) is caused by a novel coronavirus SARS-CoV-2 ([@R1], [@R2]), which is closely related to SARS-CoV, the virus underlying the 2003 SARS outbreak ([@R3]). As a positive-sense, single-stranded RNA virus bearing a membrane envelope, coronavirus enters cells when this membrane envelope fuses with host membranes ([@R4]). Previous studies showed that the entry of SARS-CoV is primarily mediated by ACE2-dependent endocytosis ([@R5], [@R6]), and new evidence suggests that SARS-CoV-2 may follow the same entry path ([@R1], [@R7]). Specifically, limiting the production of phosphatidylinositol 4,5-bisphosphate (PIP2) inhibits the fusion of the SARS-CoV-2 envelop with the endolysosomes and subsequent viral entry ([@R8], [@R9]). Additionally, entry-associated membrane fusion requires several host proteases, including the lysosome-localized Cathepsin B/L and TMPRSS2 ([@R10]--[@R12]). The fact that increasing the lysosomal pH in either TMPRSS2 positive Caco-2 or TMPRSS2 negative HEK293 cells both significantly inhibits SARS-CoV-2 cell entry ([@R10]) also suggests the endolysosome as a major entry site for SARS-CoV-2.

Our previous study on the intercellular transmission of misfolded α-Synuclein (α-Syn) fibrils, a cellular process reminiscent of viral infection, revealed an endocytosis mechanism by which the cell surface heparan sulfate proteoglycans (HSPGs) facilitate receptor-mediated uptake of protein assemblies bearing excess positive charges ([@R13]). Strikingly, this mechanism can be coopted by certain viruses and pathogens to establish productive infection ([@R13], [@R14]). To identify drugs that can diminish the spreading of misfolded α-Syn and the associated Parkinsonism ([@R15]), we screened and found eight FDA-approved drugs that block the endocytosis of preformed α-Syn fibrils (see below). Intriguingly, one of the candidates Tilorone, was recently reported as an inhibitor for SARS-CoV-2 infection ([@R16]). This coincidence, together with reports that the SARS-CoV-2 Spike can interact with heparin ([@R17], [@R18]) and that treating cells with heparinase or heparin inhibits SARS-CoV cell entry ([@R19]) prompted us to investigate the possibility of targeting HSPG-dependent endocytosis as a COVID-19 therapeutic strategy.

Heparin or knockdown of *HSPG biosynthetic enzymes* mitigates ACE2-mediated coronavirus entry {#S1}
=============================================================================================

To study coronavirus cell entry, we used luciferase-expressing pseudoviral particles (PPs) bearing SARS-CoV or SARS-CoV-2 Spike to infect Calu-3 (human lung epithelial cells positive for TMPRSS2) or HEK293T (human embryonic kidney cells negative for TMPRSS2) cells. Incubating cells with PPs resulted in luciferase expression consistently higher than the background (non-infected cells), although the increase was at most modest. By contrast, in HEK293T cells stably expressing ACE2-GFP, transduction with SARS-CoV or SARS-CoV-2 PPs resulted in luciferase expression \~170-fold higher than the background ([Fig. S1A](#SD1){ref-type="supplementary-material"}--[D](#SD1){ref-type="supplementary-material"}). These results suggest that these PPs use an ACE2-dependent mechanism to enter cells, and thus establish Calu-3 and ACE-GFP cells as relevant models representing cells with different sensitivity to infection.

To investigate the role of HSPGs in coronavirus entry, we first treated Calu-3 or ACE2-GFP cells with heparin, a Spike-binding glycan structurally related to heparan sulfate in HSPG ([Figure 1A](#F1){ref-type="fig"}). For experiments in Calu-3 cells, we monitor cell viability in the absence of viral transduction as a control for compound cytotoxicity. In ACE-GFP cells, ACE-GFP expression was used to control the confounding factors such as drug effects on gene expression or cell growth ([Figure 1B](#F1){ref-type="fig"}). Heparin treatment did not significantly induce cytotoxicity (Data not shown), but dose-dependently mitigated the luciferase signals associated with the entry of both SARS-CoV and SARS-CoV-2 PPs, with a more significant effect on SARS-CoV ([Figure 1C](#F1){ref-type="fig"}). This phenotype correlated inversely with the affinity of ACE2 to the Spike proteins from these viruses ([@R12], [@R20], [@R21]). Likewise, heparin also reduced luciferase expression in SARS-CoV or SARS-CoV-2-treated ACE2-GFP cells ([Figure 1D](#F1){ref-type="fig"}). Although the level of inhibition was lower in ACE2-GFP cells than in Calu-3 cells, a similar differential effect on the two viruses was observed. These data support a model in which heparin competitively inhibits coronavirus entry, but at sub-maximum inhibition, this effect could be offset by the increased affinity of Spike to ACE2 or by increased ACE2 expression.

Next, we used small interfering RNA (siRNA) or CRISPR to disrupt genes encoding HSPG biosynthetic enzyme XYLT2 and SLC35B2 ([Figure 1E](#F1){ref-type="fig"}, [Fig. S1E](#SD1){ref-type="supplementary-material"}--[G](#SD1){ref-type="supplementary-material"}). *XYLT2* encodes one of the two HSPG chain initiation enzymes, whereas SLC35B2 is a Golgi-localized transporter for 3'-phosphoadenosine 5'-phosphosulfate (PAPS), which is essential for chain sulfation ([@R22]). Knockdown of *XLYT2* by \~80% differentially inhibited SARS-CoV and SARS-CoV-2 PP entry similarly as heparin treatment ([Figure 1F](#F1){ref-type="fig"}). By contrast, CRISPR-mediated inactivation of *SLC35B2* inhibited the entry of SARS-CoV and SARS-CoV-2 more dramatically, but to a similar level ([Figure 1G](#F1){ref-type="fig"},). Analyses of GFP fluorescence in cell extracts showed no effect of *SCL35B2* deficiency on ACE2-GFP expression ([Fig. S1H](#SD1){ref-type="supplementary-material"}). Nevertheless, knockout of *SLC35B2* significantly abolished the binding of SARS-CoV-2 PPs to ACE2-GFP cells ([Figure 1H](#F1){ref-type="fig"}, [I](#F1){ref-type="fig"}). Altogether, these results support a model in which HSPGs serve as a virus-recruiting factor to assists ACE2 in coronavirus cell entry.

A drug repurposing screen identifies inhibitors of HSPG-dependent endocytosis {#S2}
=============================================================================

HSPGs, as negatively charged biopolymers, can recruit ligands bearing positive charges to the cell surface to promote their endocytosis ([@R14]). Our interest in drugs capable of reducing HSPG-dependent uptake of α-Syn filamentous inclusions led us to a quantitative high-throughput screen (qHTS) ([Fig. S2A](#SD1){ref-type="supplementary-material"}), which identified 8 approved drugs that inhibited α-Syn fibril uptake in both HEK293T cells and primary neurons ([Figure 2A](#F2){ref-type="fig"}, [Fig. S2B](#SD1){ref-type="supplementary-material"}--[D](#SD1){ref-type="supplementary-material"}). Among them, Tilorone, a previously established antiviral agent ([@R23]) not only reduced α-Syn fibril uptake in mouse hippocampal neurons, but also diminished fibril-induced endogenous α-Syn phosphorylation ([Fig. S2E](#SD1){ref-type="supplementary-material"}--[H](#SD1){ref-type="supplementary-material"}), a pathologic hallmark of Parkinson's disease ([@R24]).

Additional studies using a panel of endocytosis cargos showed that the identified drugs are endocytosis inhibitors with a preference for HSPG ligands. Among the cargos tested, supercharged GFP (GFP+), polycation-coated DNA, and VSVG-pseudotyped lentivirus all enter cells via a *SLC35B2* dependent mechanism ([@R13]), whereas Transferrin uses a HSPG independent but clathrin-dependent endocytosis pathway. The cholera toxin B chain (CTB) reaches the Golgi apparatus via a clathrin-independent mechanism ([@R25]). None of the drugs affected the internalization of CTB, but Sunitinib and BNTX appeared to disrupt the perinuclear stacking of the Golgi system ([Fig. S3A](#SD1){ref-type="supplementary-material"}, [B](#SD1){ref-type="supplementary-material"}). These drugs also had little impact on Transferrin endocytosis ([Fig. S3C](#SD1){ref-type="supplementary-material"}), but they could reduce the uptake of HSPG cargos to various levels ([Figure 2B](#F2){ref-type="fig"}, [Fig. S3D](#SD1){ref-type="supplementary-material"}--[F](#SD1){ref-type="supplementary-material"}) with Mitoxantrone being the most potent one: at 5 μM, it almost completely blocked the endocytosis of all HSPG cargos tested ([Figure 2B](#F2){ref-type="fig"}).

Drugs targeting HSPG-dependent endocytosis inhibit coronaviral entry {#S3}
====================================================================

We next tested whether the identified endocytosis inhibitors could block ACE2-mediated PP entry. Indeed, when present during transduction, most of these drugs (except for Exifone and K114) could significantly reduce the entry of both SARS-CoV and SARS-CoV-2 PPs at doses that did not impose significant cytotoxicity ([Figure 2C](#F2){ref-type="fig"}--[F](#F2){ref-type="fig"}, [Fig. S4A](#SD1){ref-type="supplementary-material"}--[D](#SD1){ref-type="supplementary-material"}). Additional studies done with infectious SARS-CoV-2 in Vero E6 cells showed that several drugs (Raloxifene, BNTX, and K114) could reduce the cytopathic effect (CPE) caused by the virus. As expected, this phenotype was only seen at low doses due to the intrinsic cytotoxicity of the drugs at high doses. One exception is Tilorone, which did not show much cytotoxicity at the tested concentrations, but dose-dependently protected Vero E6 cells from virus-induced cytopathic effect (CPE) ([Figure 4G](#F4){ref-type="fig"}, [H](#F4){ref-type="fig"}, [Fig. S4E](#SD1){ref-type="supplementary-material"}, [F](#SD1){ref-type="supplementary-material"}). Together, these results show that inhibitors targeting HSPG-dependent endocytosis can also affect the entry of coronavirus, further corroborating the notion that HSPGs assist ACE2 in endocytosis-mediated coronavirus entry.

Mitoxantrone directly targets cell surface HSPGs {#S4}
================================================

Among the tested drugs, Mitoxantrone is the strongest inhibitor for HSPG-dependent endocytosis. Mitoxantrone was previously discovered as a DNA intercalator, which also inhibits type II DNA topoisomerase ([@R26], [@R27]). Accordingly, Mitoxantrone is currently approved for treatment of acute non-lymphocytic leukemia, prostate cancer, and multiple sclerosis.

Because Mitoxantrone is a blue compound absorbing light at wavelength 620 nm and 685 nm ([Figure 3A](#F3){ref-type="fig"}). we used this spectral property to trace its localization in drug-treated cells, which hinted at its cellular target. To this end, we performed subcellular fractionation using Mitoxantrone-treated cells to obtain the nucleus (1,000g pellet), mitochondria-enriched heavy membranes (7,000g pellet), light membranes (100,000g pellet), and cytosol (100,000g supernatant) fractions ([Figure 3B](#F3){ref-type="fig"}, top panel). Although blue color was seen in every pellet fraction, Mitoxantrone in the nucleus and heavy membrane fraction was resistant to extraction by a buffer containing the non-ionic detergent NP40 or 1% SDS, probably due to tight association with DNA. By contrast, Mitoxantrone in the light membranes (containing the plasma membrane and endoplasmic reticulum as demonstrated by immunoblotting, middle panel) could be readily released by an NP40-containing buffer and detected by a spectrometer ([Figure 3B](#F3){ref-type="fig"}). No Mitoxantrone was detected in the cytosol fraction. Thus, in addition to DNA, Mitoxantrone also binds to cell membranes.

Several lines of evidence suggest that Mitoxantrone inhibits endocytosis and viral entry by targeting the cell surface HSPGs. First, the amount of P100-associated Mitoxantrone from *SLC35B2* deficient cells was significantly lower than that of wild-type cells, which could be rescued by re-expression of SLC35B2 ([Figure 3C](#F3){ref-type="fig"}). Thus, the binding of Mitoxantrone to light membranes appears to be in part mediated by HSPGs. Consistent with this interpretation, Mitoxantrone could readily bind to heparin beads but not to a Sepharose control ([Figure 3D](#F3){ref-type="fig"}). Intriguingly, Banoxantrone, a structurally related drug, did not bind to heparin ([Fig. S5](#SD1){ref-type="supplementary-material"}), which suggests a specific and direct interaction between Mitoxantrone and heparin and explains the SLC35B2-dependent association of Mitoxantrone with cell membranes. Importantly, compared to Mitoxantrone, Banoxantrone failed to interact with cell membranes ([Figure 3E](#F3){ref-type="fig"}), and coincidentally, it was much weaker to reduce SARS-CoV-2 PP entry into host cells ([Figure 3F](#F3){ref-type="fig"}). Surprisingly, while several weaker inhibitors but not Mitoxantrone could rescued the CPE of SARS-CoV-2 in Vero E6 cells ([Figure 2G](#F2){ref-type="fig"}, [H](#F2){ref-type="fig"}, [Fig. S4](#SD1){ref-type="supplementary-material"}), which might be due to the relatively high cytotoxicity of Mitoxantrone. In this regard, it is compelling to see that the dose-dependent toxicity profiles of Mitoxantrone and Banoxantrone were indistinguishable ([Figure 3G](#F3){ref-type="fig"}). The uncoupling of the antiviral and the anti-cancer activities of Mitoxantrone suggests the possibility of generating similar antiviral compounds with reduced cytotoxicity.

Sunitinib and BNTX disrupt actin dynamics to impair HSPG-dependent viral entry {#S5}
==============================================================================

The endocytosis of many HSPG-dependent cargos requires the actin cytoskeleton ([@R13]). We therefore determined whether the newly identified drugs affect the actin network using U2OS cells stably expressing Tractin-EGFP, an actin filament label ([@R28]). Confocal microscopy showed that most drugs did not change the actin network except for Sunitinib, an anti-cancer agent, and BNTX, an opioid receptor antagonist ([Figure 4A](#F4){ref-type="fig"}, [Fig. S6A](#SD1){ref-type="supplementary-material"}). In untreated cells, actin monomers polymerize near peripheral membranes, forming a microfilament network with many parallel actin filaments ([Fig. S6A](#SD1){ref-type="supplementary-material"}). Additionally, a meshwork of actin is associated with the cell cortex, and thick actin bundles named stress fibers are often found near basal membranes. In cells exposed to Sunitinib, the actin microfilaments were frequently replaced by short disoriented actin segments. Many cells also contained an increased number of filopodia. By contrast, cells treated with BNTX had significantly reduced actin filaments, and many cells contained actin-bearing aggregates. These phenotypes were further confirmed by TIRF microscopy analysis of membrane-associated actin in drug-treated cells ([Fig. S6B](#SD1){ref-type="supplementary-material"}).

To further elucidate the mechanistic actions of Sunitinib and BNTX, we used live-cell imaging to monitor the acute changes in actin dynamics in drug-treated cells. Shortly after Sunitinib treatment, we observed extensive de novo actin filament formation ([Figure 4B](#F4){ref-type="fig"}, [C](#F4){ref-type="fig"}, [Supplementary movies 2](#SD1){ref-type="supplementary-material"} vs. [1](#SD1){ref-type="supplementary-material"}). Actin polymerization was also detected in the cell periphery where it drove filopodium formation ([Figure 4B](#F4){ref-type="fig"}) but was not seen near basal membranes where stress fibers were located (Supplementary movie 4 vs. 3). Unlike Sunitinib, BNTX treatment caused actin filaments to disassemble in the peripheral cortex, resulting in rapid shrinking of actin microfilaments and the loss of membrane ruffling ([Figure 4D](#F4){ref-type="fig"}, [E](#F4){ref-type="fig"}, [Supplementary movies 6](#SD1){ref-type="supplementary-material"} vs. [5](#SD1){ref-type="supplementary-material"}). Together, these data suggest that Sunitinib promotes actin assembly to form disoriented filaments, while BNTX disrupts the cortex actin meshwork either by promoting actin disassembly or inhibiting actin assembly. The fact that two structurally unrelated actin inhibitors both block coronavirus entry strongly suggests that the endocytosis of coronavirus requires the actin cytoskeleton. Accordingly, SARS-CoV-2 cell entry was also sensitive to Latrunculin A, a well-established actin inhibitor ([Figure 4F](#F4){ref-type="fig"}). These findings, together with the fact that a previous drug screen identified Sunitinib as an entry inhibitor for Ebola virus ([@R29]), suggest that the actin network may paly a previously unappreciated role in the entry of many viruses into host cells.

Combination regimens target HSPG-assisted viral entry {#S6}
=====================================================

Lastly, we used gene expression profile as a signature to distinguish the action of Tilorone, Raloxifene (a hormone therapy agent for bone loss), Piceatannol (an anti-inflammatory drug), and Mitoxantrone. We treated HEK293T cells with these drugs for 6 h at a dose that imposed a significant inhibition on viral entry. Differential gene expression analyses showed that Mitoxantrone had the most significant impact on gene expression ([Figure 5A](#F5){ref-type="fig"}), consistent with its relatively high cytotoxicity. By contrast, Tilorone had the smallest effect, altering only a limited number of genes with small changes ([Fig. S7A](#SD1){ref-type="supplementary-material"}--[D](#SD1){ref-type="supplementary-material"}). Cluster analysis showed that the gene expression signature associated with Raloxifene treatment was more similar to that of Piceatannol-treated cells than to Tilorone- or Mitoxantrone-treated cells ([Figure 5A](#F5){ref-type="fig"}), suggesting that Tilorone uses a mechanism distinct from the other drugs, therefore, raising the possibility of combining Tirolone with other drugs to achieve stronger inhibition of viral entry. Indeed, in our initial trial, while Tilorone by itself required high doses to inhibit SARS-CoV-2 PP entry, co-treatment with Sunitinib, BNTX, Raloxifene, or Piceatannol all significantly enhanced the inhibition of SARS-CoV-2 PP entry by Tilorone, while Mitoxantrone modestly increased Tilorone's activity ([Figure 5B](#F5){ref-type="fig"}--[F](#F5){ref-type="fig"}). Importantly, no synergy in cytotoxicity was observed between Tilorone and other drugs ([Figure 5G](#F5){ref-type="fig"}).

While ACE2-mediated coronavirus entry into host cells is known to be controlled by a protease-dependent priming step ([@R10]--[@R12]), evidence presented here supports an additional layer of regulation by the cell surface HSPGs, which consist of two protein families (6 Glypicans and 4 Syndecans) ([@R22]). These proteins all bear negative charge-enriched heparan sulfate polymers that can promote the interaction of cells with a variety of endocytic ligands including viruses and pathogens ([@R14]). Our data suggest that HSPGs help to recruit SARS-CoV-2 to the cell surface, which should increase its local concentration for effectively engaging ACE2. Additionally, HSPGs might have a role downstream of viral recruitment given the observed binding of heparin to Spike, which induces a conformational change in the latter ([@R17]). Although our study focuses on coronavirus, drugs targeting HSPG-dependent endocytosis may have broad antiviral activities. Consistent with this view, Tilorone has long been recognized as a general antiviral agent outside the US. An early study in mice showed that Tilorone administrated orally might upregulate interferon production ([@R30]), but our gene expression study did not reveal significant changes in interferon expression by Tirolone. Instead, the demonstration of Tilorone as an endocytosis inhibitor offers an alternative explanation for its antiviral function. Importantly, our study also suggests that Tilorone, when combined with other endocytosis inhibitors can generate a promising anti-viral synergism. Thus, systematically testing combinations among drugs targeting different aspects of the coronaviral infectious cycle may offer a quick path to an effective treatment that benefits all COVID-19 patients.
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![HSPGs facilitate ACE2-mediated entry of SARS-CoV and SARS-CoV-2.\
(**A**) The chemical structures of heparan sulfate and heparin.\
(**B**) The experimental scheme for inhibitor testing.\
(**C**) Heparin competitively mitigates the entry of SARS-CoV and SARS-CoV-2 pseudoviral particles (PP). Calu-3 cells were transduced with SARS-CoV and SARS-CoV-2 PPs in the presence different heparin concentrations. The luciferase expression 48 h post-transduction indicates viral entry. Error bars indicate SEM, N=4.\
(**D**) As in C, except that ACE2-GFP HEK293T cells were used.\
(**E**) The HSPG biosynthetic pathway. Genes chosen for knockdown or knockout (KO) are in red.\
(**F**) Knockdown of *XYLT2* reduces SARS-CoV and SARS-CoV-2 PP entry. ACE2-GFP cells transfected with either control or *XYLT2* siRNA were transduced with SARS-CoV or SARS-CoV-2 PPs for 24 h before the ratio of luciferase/GFP was determined. A parallel experiment done without the virus provides a control for the effect of gene knockdown on cell viability. Error bars indicate SEM, N=4. \*\*, *p*\<0.01, \*\*\*\*, *p*\<0.0001 by unpaired Student t-test.\
(**G**) *SCL35B2* is required for SARS-CoV and SARS-CoV-2 cell entry. As in F, except that control or *SLC35B2* CRISPR KO cells were used.\
(**H** and **I**) *SLC35B2* promotes efficient binding of SARS-CoV-2 PPs to cells. (H) ACE2-GFP cells were spin-infected at 4 °C for 1h as indicated. After washing, virus bound to the cells was detected by immunoblotting. (I) The binding of SARS-CoV-2 PPs to control and *SLC35B2* deficient cells was analyzed by immunoblotting. S and S2 indicate full length and the protease-cleaved S2 domain, respectively. \*, non-specific band.](nihpp-2020.07.14.202549-f0001){#F1}

![Drugs targeting HSPG-dependent endocytosis also mitigate coronavirus entry.\
(**A**) Dose dependent inhibition of pHrodo red-labeled α-Syn fibril uptake. HEK293T cells were incubated with 400 nM pHrodo red-labeled α-Syn fibrils for 3 h in the presence of the indicated drugs. The integrated fluorescence (FL) signals were determined by flow cytometry.\
(**B**) A heat map summary of the endocytosis inhibitory activities for the indicated drugs. All drugs were tested at 10 μM except for Sunitinib and Mitoxantrone (5 μM each). See [Supplementary Figure 3](#SD1){ref-type="supplementary-material"} for details.\
(**C**-**F**) Inhibition of SARS-CoV and SARS-CoV-2 PP entry by HSPG endocytosis inhibitors. HEK293 cells stably expressing ACE2-GFP were incubated with SARS-CoV or SARS-CoV-2 PPs in the presence of the indicated drugs. Percent of PP entry was determined by the luciferase level. Cells treated with the inhibitors without the PPs were used to determine drug cytotoxicity. Shown is a representative experiment from two independent repeats with similar results. Cpd, Compound. Error bars indicate SEM, N=4.\
(**G** and **H**) Tilorone and Raloxifene protects Vero E6 cells from SARS-CoV-2-induced cytotoxicity. Viability of Vero E6 cells were measured after treatment with the indicated drugs in the presence of SARS-CoV-2 (black curves) or without the virus (orange curves). (CPE, Cytopathic effect). Error bars indicate SEM, N=2.](nihpp-2020.07.14.202549-f0002){#F2}

![Mitoxantrone directly targets HSPGs on the cell surface.\
**(A)** The chemical structures and absorbance spectra of Mitoxantrone (MTAN) and Banoxantrone (BANO).\
**(B)** The subcellular distribution of Mitoxantrone. The scheme illustrates the experimental procedure. HEK293T cells were treated with 5 μM Mitoxantrone for 30 min at 37 °C before fractionation. The membrane pellet (P100) and cytosol supernatant (S100) fractions were analyzed by immunoblotting and by a spectrometry at the indicated wavelengths. Error bars indicate SEM. N=3.\
**(C)** The membrane association of Mitoxantrone depends on *SLC35B2 (35B2)*. Cells of the indicated genotypes were treated with 5 μM Mitoxantrone for 30 min at 37 °C and then fractionated as in B. The absorbances of the P100 fractions were measured. The absorbance of the control sample at 680 nm was used for normalization. Bottom panels show the cells stained with DAPI (blue) and GFP+ (green) to label DNA and HSPG (Green), respectively. Error bars indicate SEM. N=3.\
**(D)** Mitoxantrone binds heparin Sepharose. Mitoxantrone (50 μM) was incubated with either control Sepharose or heparin (HP)-coated Sepharose for 5 min. The picture shows the samples after centrifugation. The graph shows the absorbance spectra of the supernatant fractions.\
**(E)** Banoxantrone does not bind to cell membranes. Cells treated with either Mitoxantrone or Banoxantrone at 5 μM for 30 min were fractionated and the absorbance spectra of the P100 fractions were measured. The picture shows the cell pellets after treatment.\
**(F)** Banoxantrone has reduced antiviral activity. ACE2-GFP cells were incubated with SARS-CoV-2 in the presence of the indicated drugs. Error bars indicate SEM. Dashed lines indicate 95% confidence interval. N=4.\
**(G)** The cytotoxicity profiles or Mitoxantrone and Banoxantrone in ACE2-GFP-expressing HEK293T cells. Error bars indicate SEM. N=3.](nihpp-2020.07.14.202549-f0003){#F3}

![The actin cytoskeleton network is required for coronavirus entry.\
(**A**) The chemical structures of Sunitinib and BNTX.\
(**B** and **C**) Sunitinib stimulates actin filament formation at the cell periphery. (B) Confocal snapshots of a U2OS cell stably expressing Tractin-EGFP before or after Sunitinib (5 μM) treatment. The red arrows indicate new actin filaments formed in a direction perpendicular to the existing filaments. The inset shows an enlarged view of the box. (C) Live cell imaging of actin filament formation after Sunitinib treatment (5 μM, 60min). The arrows indicate examples of actin filament assembly. The insets show an enlarged view of the boxed areas. Scale bar, 5 μm.\
(**D** and **E**) BNTX disrupts actin filaments at the cell periphery. (D) Confocal snapshots of a Tractin-EGFP cell before and after BNTX (10 μM) treatment. Arrows indicate the peripheral actin network disrupted by BNTX. (E) Live cell imaging shows the shrinking of peripheral membranes after BNTX treatment. Yellow arrowheads mark a retracting actin bundle.\
(**F**) Latrunculin A inhibits SARS-CoV-2 entry. ACE2-GFP cells incubated with SARS-CoV-2 PPs in the presence of Latrunculin were analyzed for luciferase expression (Entry). A parallel treatment in the absence of the virus showed the effect of Latrunculin A on cell viability. Error bars indicate SEM. N=dot number. \*\*\*, *p*\<0.001, \*\*\*\*, *p*\<0.0001.](nihpp-2020.07.14.202549-f0004){#F4}

![Exploring the combination regimens that optimally target ACE2-mediated coronaviral entry.\
(**A**) A heatmap showing the gene expression profiles of untreated HEK293T cells or cells treated with the indicated drugs at 10 μM for 6 h (Mitoxantrone 5 μM).\
(**B-F**) Results from a drug combination study. HEK293T-ACE2-GFP cells were incubated with SARS-CoV-2 PPs in the presence of different concentrations of Tilorone (T) either alone or together with a second drug as indicated. The ratio of luciferase/GFP from untreated cells was normalized as 100% viral entry. Error bars indicate SEM. N=4.\
(**G**) A parallel treatment in the absence of virus shows drug-associated cytotoxicity. Error bars indicate SEM. N=4.](nihpp-2020.07.14.202549-f0005){#F5}
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